• Home
  • Tag: 爱上海Pejmon

read more

first_img Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory Image courtesy of Amen Clinics Related Content News | Radiopharmaceuticals and Tracers | May 13, 2019 Blue Earth Diagnostics Expands Access to Axumin in Europe Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first… read more News | Radiopharmaceuticals and Tracers | July 16, 2019 NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-… read more News | Radiopharmaceuticals and Tracers | July 26, 2019 NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of… read more News | Radiopharmaceuticals and Tracers | May 17, 2019 New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in… read more January 16, 2013 — Lantheus Medical Imaging Inc. has added a low-enriched uranium (LEU) TechneLite (technetium Tc 99m Generator) generator to the its nuclear imaging product portfolio. Lantheus’ LEU TechneLite generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95 percent LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain. Lantheus’ first LEU TechneLite generator was shipped on Jan. 7, 2013.With the introduction of the LEU TechneLite generator, Lantheus fully supports the U.S. government’s global nuclear security strategy to encourage reliable supplies of medical radioisotopes produced from non-HEU sources. On Jan. 2, 2013, President Obama signed into law the American Medical Isotopes Production Act of 2011 (AMIPA) as part of the 2013 National Defense Authorization Act. The AMIPA encourages the domestic production of LEU Mo-99 and provides for the eventual prohibition of the export of HEU from the United States. In addition, the Centers for Medicare and Medicaid Services (CMS) recently stipulated in the 2013 final Medicare payment rules, for Medicare Hospital Outpatients, that CMS will provide incremental reimbursement for every Tc-99m diagnostic dose produced from non-HEU sourced Mo-99. Lantheus’ LEU TechneLite generator satisfies the new reimbursement requirements under the CMS 2013 rules.“We are pleased to be the first company to offer a Tc-99m generator produced using at least 95 percent LEU,” said Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. “As leaders in nuclear medicine, an important component of our global sourcing strategy is to increase our use of LEU-sourced Mo-99 with a goal of 100 percent by 2016. Our TechneLite generator is used in many critical diagnostic imaging procedures, including scans of the heart, brain, bone, kidneys and some types of tumors. The introduction of our LEU TechneLite generator expands our nuclear medicine product portfolio and meets CMS’ new reimbursement requirements for Medicare Hospital Outpatients in 2013, while supporting the government’s non-proliferation goal of moving away from the use of HEU in the production of medical isotopes.”Mo-99 is the parent isotope of Tc-99m, which is the radioisotope most widely used for nuclear imaging tests. Tc-99m is used in approximately 15 million doses in the United States annually. As a leader in the radiopharmaceutical business, Lantheus has secured the most globally diversified and balanced Mo-99 supply chain in the industry, and receives the medical isotope from four of the five major processors and seven of the eight associated reactors.In 2012, Lantheus announced expanded access to LEU-sourced Mo-99 with an extended agreement with NTP Radioisotopes in South Africa. Under the five-year agreement, Lantheus will receive an increasing supply of Mo-99 produced from LEU targets from NTP Radioisotopes (NTP) and Australian Nuclear Science and Technology Organisation (ANSTO). Additionally, Lantheus announced continued supply of Mo-99 from Nordion, which will be used in the production of the company’s non-LEU TechneLite generators.“We continue to be committed to providing a stable, balanced and reliable supply of Mo-99 to our customers,” said Cyrille Villeneuve, chief commercial officer of Lantheus Medical Imaging. “Our gradual transition to LEU-sourced Mo-99 and the addition of the LEU TechneLite generator ensures that our customers will have continued access to Tc-99m, now and in the future. We believe our LEU strategy gives us a strong position in the generator market and provides a differentiated offering for our customers.”For more information: www.technelite.com FacebookTwitterLinkedInPrint分享 News | Radiopharmaceuticals and Tracers | July 01, 2019 Bracco Imaging Acquires Blue Earth Diagnostics Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company… read more center_img News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S… read more Image courtesy of MR Solutions. News | Radiopharmaceuticals and Tracers | June 05, 2019 BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for… read more News | PET-MRI | May 23, 2019 Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (… read more Technology | January 16, 2013 Lantheus Introduces Low-Enriched Uranium (LEU) Tc-99m Generator Supports long-term strategy to eliminate use of highly enriched uranium (HEU)-produced molybdenum and technetium News | Radiopharmaceuticals and Tracers | August 02, 2019 ASRT Supports Radiopharmaceutical Reimbursement Bill The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure… read more News | Radiopharmaceuticals and Tracers | March 14, 2019 Researchers Create New Method for Developing Cancer Imaging Isotopes A team of researchers at the University of Washington announced they developed a new automated system for producing… read morelast_img read more